lumefantrine

lumefantrine is a key antimalarial medication used in combination with artemether to treat acute, uncomplicated *Plasmodium falciparum* malaria. This combination therapy, marketed as Coartem, is on the World Health Organization Model List of Essential Medicines and is a cornerstone of modern malaria treatment protocols. It belongs to the aryl amino alcohol class of drugs and works by interfering with hemozoin formation within the malaria parasite.

Medical uses

The primary medical use is in fixed-dose combination with artemether for treating uncomplicated malaria caused by *Plasmodium falciparum*, including in regions with known resistance to drugs like chloroquine and sulfadoxine/pyrimethamine. This artemisinin-based combination therapy is recommended by the World Health Organization and is widely deployed by organizations such as Médecins Sans Frontières and the Global Fund to Fight AIDS, Tuberculosis and Malaria. It is not indicated for severe malaria, which requires parenteral treatment with agents like artesunate, nor for prophylaxis against malaria infection.

Adverse effects

Common adverse effects are generally mild and include headache, dizziness, anorexia, and nausea. A significant concern is its potential to prolong the QT interval on an electrocardiogram, which increases the risk of cardiac arrhythmias, particularly when co-administered with other QT-prolonging drugs like certain antipsychotics or macrolide antibiotics. Other reported effects can involve pruritus and abdominal pain. Safety in pregnancy is categorized as likely acceptable by organizations like the Centers for Disease Control and Prevention, though use should be under medical supervision.

Pharmacology

Its mechanism of action involves inhibition of hemozoin biocrystallization, a process essential for detoxifying free heme released during hemoglobin digestion by the parasite. This leads to toxic heme accumulation that lyses the parasite. Pharmacokinetically, it is a highly lipophilic compound with variable and slow absorption, significantly enhanced by co-administration with fatty food. It is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP3A4, and has a very long elimination half-life of about 3-6 days, which provides a prolonged post-treatment prophylactic effect.

History

The drug was discovered in the 1970s by the Academy of Military Medical Sciences in China as part of Project 523, the same military research program that discovered artemisinin. It was developed under the name benflumetol. The fixed-dose combination with artemether was later developed through a collaboration between Novartis and Chinese research institutes. It received approval from the European Medicines Agency and was added to the WHO Model List of Essential Medicines, becoming a critical tool in global malaria control efforts led by the Roll Back Malaria Partnership.

Society and culture

It is listed on the World Health Organization Model List of Essential Medicines and is a vital component in the global fight against malaria. The combination product Coartem has been provided at cost to public health agencies in endemic countries through initiatives by Novartis and procurement by entities like the President's Malaria Initiative. Its role is highlighted in treatment guidelines from the Centers for Disease Control and Prevention and the World Health Organization. The development and deployment of this therapy represent a significant achievement in tropical medicine and international public health collaboration.

Category:Antimalarial agents Category:World Health Organization essential medicines Category:Piperidines